Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire•12/11/2026•16:01 ET
0
Key Highlights
- ➤Mirum grants options for 26,126 shares and RSUs for 34,386 shares
- ➤17 new employees receive inducement awards under Mirum’s 2020 Inducement Plan
- ➤Stock options carry a $94.42 exercise price and vest over four years
- ➤RSUs vest over three years, subject to continued employee service
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on November 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 26,126 shares of common stock and 34,386 restricted stock units (“RSUs”) to 17 new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Get started
Create a free account to read the full story.